New Apheresis Treatment Shows Promise for Pre-eclampsia Patients

Researchers at Cedars Sinai Health Sciences University have developed an apheresis procedure to filter out the toxic protein sFlt-1, which is linked to blood vessel damage in pre-eclampsia.

In clinical trials involving 16 women, the treatment reduced mean arterial blood pressure by 4.1 mmHg and successfully extended pregnancies by up to 10 additional days.

Pre-eclampsia, characterized by systolic blood pressure at or above 140 mm/Hg, remains the third leading cause of maternal death globally, often necessitating premature childbirth to save lives.